A 62-year-old woman with newly diagnosed stage IIIA NSCLC (T3N2M0, adenocarcinoma) is being evaluated for treatment. She has adequate pulmonary function (FEV1 65% predicted) and no significant comorbidities. Molecular testing shows EGFR mutation (exon 19 deletion). What is the most appropriate next step in management?

Explanation

## Clinical Context Stage IIIA NSCLC with N2 involvement is locally advanced and potentially resectable. The presence of EGFR mutation is important for future treatment but does not change the immediate management strategy for stage IIIA disease. ## Why Mediastinal Staging (EBUS) Is Critical **Key Point:** N2 disease (ipsilateral mediastinal lymph nodes) is heterogeneous: - **Resectable N2:** Single station, easily accessible, no extranodal extension → candidate for surgery ± neoadjuvant therapy - **Unresectable N2:** Multiple stations, bulky disease, extranodal extension → requires chemoradiation **High-Yield:** EBUS with fine-needle aspiration (FNA) is the gold standard for mediastinal lymph node staging. It provides: - Tissue confirmation of N2 involvement - Assessment of lymph node size, location, and number of stations - Guides decision between surgical and non-surgical approaches ## Staging Hierarchy for Stage IIIA ```mermaid flowchart TD A[Stage IIIA NSCLC with N2]:::outcome --> B[Mediastinal staging: EBUS-FNA]:::action B --> C{Resectable N2?}:::decision C -->|Yes, single station| D[Neoadjuvant chemo + surgery]:::action C -->|No, bulky/multiple stations| E[Concurrent chemoradiation]:::action D --> F[Reassess post-neoadjuvant]:::action E --> G[Consider consolidation therapy]:::action ``` ## Why Not EGFR TKI Monotherapy? **Warning:** EGFR mutation is a **predictive marker for response to TKIs in advanced/metastatic disease**, not for stage IIIA locally advanced cancer. Stage IIIA requires aggressive locoregional therapy (surgery ± chemotherapy or chemoradiation) regardless of molecular status. TKI monotherapy is reserved for stage IV or recurrent disease. **Clinical Pearl:** In stage IIIA, curative intent requires multimodal therapy. EGFR mutation status informs second-line or maintenance therapy if needed, but does not replace the standard of care for locally advanced disease. ## Treatment Sequencing | Stage IIIA Scenario | Management | |---|---| | Resectable N2 (EBUS confirms) | Neoadjuvant chemotherapy → surgery → adjuvant therapy if indicated | | Unresectable N2 (bulky, multiple stations) | Concurrent chemoradiation (platinum + pemetrexed/gemcitabine + 60 Gy RT) | | Borderline resectable | Neoadjuvant chemo ± immunotherapy → reassess | [cite:NCCN NSCLC Guidelines 2023; Harrison 21e Ch 89]